Salute e Benessere

Hansa Biopharma plans restructuring to strengthen long-term competitiveness and…

As part of the restructuring, Hansa will notify the Swedish Public Employment Service (Sw. Arbetsförmedlingen) and seek consultations with the trade unions regarding the reorganisation. Decisions regarding employee reductions will take place after the change consultations have been concluded according to local regulations. As part of the restructuring, Hansa will notify the Swedish Public Employment Service (Sw.Arbetsförmedlingen ) and seek consultations with the trade unions regarding the...
PR Newswire
05/12/2023

Single-Use Bioprocessing Market Revenue to Cross USD 39.19 million by 2035, Due…

The global single use bioprocessing market size was estimated at USD 8.45 million in 2023 and is expected to reach over USD 39.19 million by 2035, growing at a compounded annual growth rate (CAGR) of 14% in the forecast period 2022-2035. The global single use bioprocessing market size was estimated atUSD 8.45 millionin 2023 and is expected to reach overUSD 39.19 millionby 2035, growing at a compounded annual growth rate (CAGR) of 14% in the forecast period 2022-2035. Over the...
PR Newswire
05/12/2023

Home Decor Market to Reach $1.1 Billion, Globally, by 2032 at 4.9% CAGR: Allied…

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/751 Request Sample Copy of Report:https://www.alliedmarketresearch.com/request-sample/751 Prime determinants of growth The home decor market is a dynamic and ever-evolving industry, shaped by a blend of prevailing trends, growth factors, and industry obstacles. Notably, the industry is witnessing surge in sustainability practices and environmentally conscious product choices as a prominent trend...
PR Newswire
05/12/2023

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2023

Accumulated revenue for January – November 2023 increased by 22 % to SEK 1609.6 (1314.2) million. Accumulated revenue for January –November 2023increased by 22 % toSEK 1609.6(1314.2) million. Revenues were distributed as follows: Countries in regions:-The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &...
PR Newswire
05/12/2023

Mission Therapeutics granted MHRA Clinical Trial Authorisation (CTA) for MTX325…

Dr Paul Thompson, Chief Scientific Officer, Mission Therapeutics, said: "There are currently no approved treatments for Parkinson's Disease which modify the underlying pathology of this common and devastating degenerative condition. By enhancing mitophagy, MTX325 is designed to address the loss of dopamine-producing neurons resulting from the build-up of dysfunctional mitochondria in these brain cells. Mitophagy is the natural 'quality control system' cells use to clear out dysfunctional…
PR Newswire
05/12/2023

Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer

Commenting on the appointment, Michael Koslowski, Chief Executive Officer of Kling Bio, said: "Kling will benefit immensely from Stefano's proven leadership skills and in-depth scientific knowledge. I am confident Stefano will help guide and execute our vision for Kling during this pivotal phase of Company growth, as we accelerate to become a world-leading drug discovery and development company." Commenting on the appointment,Michael Koslowski, Chief Executive Officer ofKling Bio…
PR Newswire
05/12/2023

Cylera Named Leader in Connected Medical Device Security Solutions Report

Customers can see the full competitive ratings and obtain the report by visiting https://resources.cylera.com/2023_cmdss_report. Customers can see the full competitive ratings and obtain the report by visitinghttps://resources.cylera.com/2023_cmdss_report. Ranked among the highest in the Customer Impact category and listed overall as one of the top global providers in connected medical device security, the report described how Cylera's IoT intelligence and security platform can readily...
PR Newswire
05/12/2023

J INTS BIO Gives Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th…

Currently, the company is conducting a global phase 1/2 clinical study to evaluate the safety, pharmacokinetics, and anti-tumor activity of "JIN-A02" in patients with advanced NSCLC carrying EGFR mutations. Currently, the company is conducting a global phase 1/2 clinical study to evaluate the safety, pharmacokinetics, and anti-tumor activity of "JIN-A02" in patients with advanced NSCLC carrying EGFR mutations. During ESMO Asia, the safety and PK results for the first two…
PR Newswire
05/12/2023

Philogen S.p.A. announces receipt of the Good Manufacturing Practice Certificate…

Agenzia Italiana del Farmaco(AIFA) following an inspection occurred in July 2023. AIFA confirmed that Philogen new facility complies with the requirements and guidelines of Good Manufacturing Practice outlined in the Directive 2003/94/EC issued by the European Parliament. In the European Union, national competent authorities - AIFA in Italy - are responsible for inspecting manufacturing sites based within their own territories. Sites located in one European Member State also benefit from...
Nasdaq GlobeNewswire
05/12/2023

Implantica announces live surgery with RefluxStop™ attended by nearly 2'000…

Prof. Bonavina said, "It is inspiring to see the emergence of a new anti-reflux surgical solution, RefluxStop™, that has been tested in more than 600 patients across Europe with very promising results. I think its simple design and unique approach to treating GERD by restoring the natural anatomy instead of constricting or encircling the esophagus done in traditional techniques, offers a novel way of treating a hugely underserved patient population that is seeking a long-term solution to…
PR Newswire
05/12/2023

Mendus to present at Cell & Gene Therapy Manufacturing & Commercialization…

Press ReleaseStockholm, Sweden, December 5, 2023Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced it will present the development of a robust, scaled up industrial process for vididencel supply at the Cell & Gene Therapy Manufacturing & Commercialization Conference held Dec 4-6 in Dublin.Mendus Chief Technology Officer Leopold Bertea will chair the Cell Therapy Manufacturing &...
Nasdaq GlobeNewswire
05/12/2023

Clarivate Expands Partnership with VeriSIM Life to Accelerate and De-risk…

The new solution serves as the next phase of an expanding partnership between Clarivate and VeriSIM Life, the leading artificial intelligence (AI)-enabled, R&D decisions de-risker for breakthrough drug development, announced earlier this year. The new solution serves as the next phase of an expanding partnership between Clarivate and VeriSIM Life, the leading artificial intelligence (AI)-enabled, R&D decisions de-risker for breakthrough drug development, announced earlier this year...
PR Newswire
05/12/2023

Body Lotion Market to Reach $85.3 billion, Globally, by 2032 at 4.3% CAGR…

Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/6688 Request Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/6688 Prime determinants of growth Rise in awareness about skin health & adoption of healthier lifestyle are the prime factors for growth of body lotion market. With widespread knowledge about the skin problems that arise from insufficient skincare, consumers are becoming more aware about the damage it does to...
PR Newswire
05/12/2023

Digital Twin Market Size to Surpass USD 29.8 billion by 2035, Registering at a…

The global digital twin market size was estimated at USD 1.2 billion in 2022 and is expected to reach over USD 29.8 billion by 2035 at a compounded annual growth rate (CAGR) of 30% in the forecast period 2022-2035. The global digital twin market size was estimated atUSD 1.2 billion in 2022 and is expected to reach overUSD 29.8 billion by 2035 at a compounded annual growth rate (CAGR) of 30% in the forecast period 2022-2035. A digital twin is a virtual model that resembles a...
PR Newswire
05/12/2023

IBA signs research collaboration agreement with the University of Kansas Medical…

Louvain-La-Neuve, Belgium, December 5, 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of proton therapy solutions for the treatment of cancer, announced today a research collaboration agreement with the University of Kansas Medical Center (KUMC) to advance preclinical research into the use of ConformalFLASH ®1technology using an IBA Proteus ® ONE 2machine. The preclinical evaluation will be...
Nasdaq GlobeNewswire
05/12/2023

Chiesi explores the impact of climate change on people living with respiratory…

Chiesi recognizes the importance of prioritizing patients in healthcare solutions and policy designs aimed at fighting climate emergency. This message is at the forefront of Chiesi's dedicated episode in "The Climate and Us" series. Chiesi recognizes the importance of prioritizing patients in healthcare solutions and policy designs aimed at fighting climate emergency. This message is at the forefront of Chiesi's dedicated episode in "The Climate and Us" series. Titled…
PR Newswire
05/12/2023

Novadip Biosciences SA announces significant clinical milestones for both of its…

MONT SAINT-GUIBERT, Belgium, Dec. 5, 2023 /PRNewswire/ -- Novadip Biosciences SA ("Novadip" or "the Company"), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that the first US patient has been implanted with its investigational tissue regeneration product, NVD-003, in its Phase 1b/2a clinical trial in Congenital Pseudarthrosis of…
PR Newswire
05/12/2023

Roche announces positive Phase III results for inavolisib combination in people…

Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting PIK3CAmutations, found in approximately 40% of HR-positive breast cancers, are linked to tumour growth, disease progression, and treatment resistance 1,2Data will be shared with health authorities and presented at an upcoming medical meeting Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY)...
Nasdaq GlobeNewswire
05/12/2023

Caresyntax Announces Strategic Collaboration with AAICO to expand AI-based…

As a priority, the collaboration will focus on healthcare insurers and payers in select European and Middle Eastern markets, with the goal of increasing the overall value of healthcare by enhancing transparency, decreasing administrative burden for clinicians and their healthcare teams, and ultimately, improving outcomes for patients. As a priority, the collaboration will focus on healthcare insurers and payers in select European and Middle Eastern markets, with the goal of increasing the...
PR Newswire
05/12/2023

Dental Milling Machine Market to Reach $4.6 billion, Globally, by 2032 at 8.5%…

Request Sample of the Report on Dental Milling Machine Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3616 Request Sample of the Report on Dental Milling Machine Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/3616 Prime determinants of growth Rise in prevalence of dental diseases, surge in demand for dental milling machine, increase in geriatric population, and rise in awareness regarding oral health and digital dentistry...
PR Newswire
05/12/2023

Surging Demand for Single-use Facial Masks Amidst Disease Outbreaks to Propel…

Get an Exclusive Sample Copy of the Disposable Face Mask Market, 2024-2034: https://www.futuremarketinsights.com/reports/sample/REP-GB-18526 Surgical mask industries witnessed an unparalleled demand during the COVID-19 pandemic. Demand for disposable face masks as a readily available and convenient tool for avoiding other infections is still high. According to non-woven face mask market insights, more people are using masks now because they are becoming more...
PR Newswire
04/12/2023

Metastatic HR+/HER2− Breast Cancer Market is Expected to Showcase a Significant…

Metastatic HR+/HER2− Breast Cancer Market Report Key Takeaways from the Metastatic HR+/HER2− Breast Cancer Market Report Key Takeaways from the Discover which therapies are expected to grab the major metastatic HR+/HER2− breast cancer market share @Metastatic HR+/HER2− Breast Cancer Market Report Metastatic HR+/HER2− Breast Cancer Overview The most frequently encountered type of breast cancer is HR+ HER2- subtype, characterized by cancer cells with estrogen and...
PR Newswire
04/12/2023

Information regarding the total number of voting rights and total number of…

Information regarding the total number of voting rights andtotal number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of theAutorité des Marchés Financiers )Market : NYSE Euronext ParisISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total =...
Nasdaq GlobeNewswire
04/12/2023

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease…

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026New York, NY, and Saint-Herblain (France), December 4, 2023– Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today...
Nasdaq GlobeNewswire
04/12/2023
Altri  Comunicati